Life sciences software firm ArisGlobal to acquire Amplexor Life Sciences

TAGS

ArisGlobal, a life sciences software provider, will acquire Amplexor Life Sciences, a software solutions provider, to create an all-inclusive regulatory SaaS platform for the life sciences industry.

The financial terms of the transaction were not disclosed.

The transaction is anticipated to accelerate both companies’ strategies and improve productivity to deliver new treatments.

With the integration of the regulatory product lines, ArisGlobal’s end-to-end technology platform LifeSphere users will now have access to larger publishing and labeling capabilities, apart from the quality management system from Amplexor Life Sciences.

See also  Kim Jong Un jumps on a train to Russia! Is World War III on the horizon?

Mike Gordon — ArisGlobal CEO said: “For many years, ArisGlobal has been focused on building a regulatory platform that provides a market-leading, comprehensive set of products and streamlines processes supporting collaboration across distributed teams while adhering to extensive and evolving global regulatory requirements.

“By combining our core functionalities, we are elevating our end-to-end Regulatory capabilities to enhance our customers’ journey.”

LifeSphere platform, on the other hand, will connect Amplexor Life Sciences’ regulatory customers to safety, medical affairs, and clinical solutions.

See also  Micron to invest $100bn in new semiconductor fabrication facility in Clay

Elvis Paćelat — Amplexor Life Sciences Executive Vice President said: “Amplexor Life Sciences has always sought to provide their customers with operational excellence in global compliance, and this new chapter of our products within the LifeSphere Regulatory platform will continue to do that.

“We are excited to join forces with ArisGlobal, who has been an innovator in the life sciences space for several decades, to provide the market with a full scope of products designed to make regulatory processes a connected, cloud-based, and compliant experience.”

See also  Kazia Therapeutics gets fast track status for paxalisib in glioblastoma

The transaction is subject to customary government approvals, which are anticipated to be completed over the next 60 days.

The US-headquartered ArisGlobal provides drug safety solutions, with regional offices in Europe, India, Japan, and China.

Amplexor Life Sciences offers regulatory, quality and safety software solutions, with offices in Europe, US, India, and the APAC region.

CATEGORIES
TAGS
Share This